12:00 AM
May 07, 2012
 |  BC Week In Review  |  Company News  |  Deals

Heparinex, Novo Nordisk deal

Heparinex's Caisson Biotech LLC subsidiary granted Novo exclusive, worldwide rights to use heparosan-based drug delivery technology to develop compounds within undisclosed indications. The technology combines a...

Read the full 106 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$30 USD
More Info >